您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > CU-CPT17e
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CU-CPT17e
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CU-CPT17e图片
CAS NO:2109805-75-4
规格:≥98%
包装与价格:
包装价格(元)
2mg电议
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 504.49
FormulaC27H24N2O8
CAS No.2109805-75-4
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 5 mg/mL
Water:<1 mg/mL
Ethanol: <1 mg/mL
SMILESO=[N+]([O-])C(C=C1)=CC=C1COC2=CC(C=CC3(CCOCC3)O4)=C4C=C2OCC5=CC=C([N+]([O-])=O)C=C5
SynonymsCU-CPT-17e; CU-CPT17e; CU CPT17e; CU-CPT 17e; CUCPT17e
实验参考方法
In Vitro

In vitro activity: CU-CPT17e is a multi-TLR(Toll-like receptor) agonist that activates TLR3, TLR8, and TLR9. Therapies based on activation of multiple Toll-like receptors (TLRs) may offer superior therapeutic profiles than that of single TLR activation. CU-CPT17e was identified from a cell-based high-throughput screening of a small-molecule library based on TLR3-mediated NF-κB activation. Biochemical studies demonstrated that CU-CPT17e could induce a strong immune response via the production of various cytokines in human monocytic THP-1 cells. Furthermore, CU-CPT17e inhibited the proliferation of HeLa cancer cells by triggering apoptosis and arresting the cell cycle at the S phase. These results showcase potential therapeutic applications of CU-CPT17e in both vaccine adjuvants and anticancer therapies based on multi-TLR activation.


Kinase Assay: CU-CPT17e shows strong NF-κB activation in TLR3, TLR8 and TLR9 HEK293 cells with EC50 values of 4.80±0.73, 13.5±0.58 and 5.66±0.17 μM, respectively. CU-CPT17e significantly improves the activity with 13.9±0.9 fold of NF-κB activation and an EC50 value of 4.8±0.7 μM. CU-CPT17e inhibits the proliferation of HeLa cancer cells by triggering apoptosis and arresting the cell cycle at the S phase. The induction of apoptosis by CU-CPT17e in HeLa cells is investigated. HeLa cells are cultured with increasing concentrations of CU-CPT17e or poly I:C or blank control (DMSO) for 24 h. Treatment with CU-CPT17e for 24 h at different concentrations (10 to 40 μM) results in an elevation of apoptotic cell population ranging from 10% to 17%, which is more effective than poly I:C at 5 μg/mL. These results suggest that the antiproliferative activity of CU-CPT17e against HeLa cells might result from its ability to directly induce apoptosis.


Cell Assay: HeLa cells are seeded at a density of 3×105 cells/well in 6-well plates and allowed to attach for 24 h. After treatment of indicated concentrations of CU-CPT17e or poly I:C (5 μg/mL) for another 24 h, cells are harvested with 0.25% trypsin without EDTA and rinsed twice with PBS, then stained using a Annexin V-FITC apoptosis detection kit. Cells are analyzed with a BD Accuri C6 flow cytometer.

In Vivo
Animal model
Formulation & Dosage
ReferencesJ Med Chem. 2017 Jun 22;60(12):5029-5044; Nat Chem Biol. 2018 Jan; 14(1): 58–64.